Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial

OBJECTIVES: Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is commonly used to reduce the incidence of gastrointestinal (GI) complications in patients with rheumatoid arthritis (RA). CELBESTA® is a generic equivalent to CELEBREX®, a celecoxib preparation. This study compared the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun-Sook, Choi, Won-Ho, Kim, Bo Young, Kim, Sung Soo, Lee, Sang-Il, Kim, Sang-Hyon, Choi, Sung Jae, Kim, Geun-Tae, Hur, Jin-Wuk, Lee, Myeung-Su, Kim, Yun Sung, Hong, Seung-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Prospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325469/
https://www.ncbi.nlm.nih.gov/pubmed/32589073
http://dx.doi.org/10.1177/0300060520931323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325469/
https://www.ncbi.nlm.nih.gov/pubmed/32589073
http://dx.doi.org/10.1177/0300060520931323

Ejemplares similares